A Prospective Study on the Metabolic and Hormonal Outcomes of SGLT2 Inhibitor Combination Therapy With and Without Metformin in Newly Diagnosed Type 2 Diabetes Mellitus.

Aftab R, Fawwad A, Abbas E, Nangrejo R, Fatima F, Shahid SM

Open source

DOI
10.3390/biomedicines14061201
Published
2026 May 27
Container
Biomedicines
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/biomedicines14061201,
  title = {A Prospective Study on the Metabolic and Hormonal Outcomes of SGLT2 Inhibitor Combination Therapy With and Without Metformin in Newly Diagnosed Type 2 Diabetes Mellitus.},
  author = {Aftab R and Fawwad A and Abbas E and Nangrejo R and Fatima F and Shahid SM},
  year = {2026},
  journal = {Biomedicines},
  doi = {10.3390/biomedicines14061201},
  url = {https://doi.org/10.3390/biomedicines14061201}
}

RIS

TY  - JOUR
TI  - A Prospective Study on the Metabolic and Hormonal Outcomes of SGLT2 Inhibitor Combination Therapy With and Without Metformin in Newly Diagnosed Type 2 Diabetes Mellitus.
AU  - Aftab R
AU  - Fawwad A
AU  - Abbas E
AU  - Nangrejo R
AU  - Fatima F
AU  - Shahid SM
PY  - 2026
JO  - Biomedicines
DO  - 10.3390/biomedicines14061201
UR  - https://doi.org/10.3390/biomedicines14061201
ER  - 

APA

R, A., A, F., E, A., R, N., F, F., & SM, S. (2026). A Prospective Study on the Metabolic and Hormonal Outcomes of SGLT2 Inhibitor Combination Therapy With and Without Metformin in Newly Diagnosed Type 2 Diabetes Mellitus.. Biomedicines. https://doi.org/10.3390/biomedicines14061201

Source records